MENU
TECH
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

TECH stock forecast, quote, news & analysis

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
TECH
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for TECH with price predictions
Oct 16, 2026

TECH in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 10, 2026

TECH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 38 cases where TECH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on TECH as a result. In 64 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

Following a +0.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where TECH advanced for three days, in 192 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

The Aroon Indicator entered an Uptrend today. In 108 of 216 cases where TECH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 58 cases where TECH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TECH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.394) is normal, around the industry mean (26.782). P/E Ratio (62.513) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (2.110) is also within normal values, averaging (9.059). TECH has a moderately high Dividend Yield (0.004) as compared to the industry average of (0.000). P/S Ratio (9.346) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TECH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TECH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Dividends

TECH paid dividends on September 04, 2026

Bio-Techne Corp TECH Stock Dividends
А dividend of $0.08 per share was paid with a record date of September 04, 2026, and an ex-dividend date of August 24, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 133.74B. VRTX holds the highest valuation in this group at 133.74B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -22%. TCRT experienced the highest price growth at 235%, while CDT experienced the biggest fall at -67%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was -21% and the average quarterly volume growth was -44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 1 (-100 ... +100)
TECH in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 10, 2026